Autor: |
Carlos L. Arteaga, Erik S. Knudsen, Wenyi Wei, Teresa C. Dugger, David A. Riddle, Michael J. Pishvaian, Paula R. Pohlmann, Melinda E. Sanders, Paula G. Ericsson, Violeta Sánchez, Mónica Valéria Estrada, Preston D. Moore, Agnieszka K. Witkiewicz, Katherine E. Hutchinson, Kyung-Min Lee, Luigi Formisano, Joshua A. Bauer, Neil E. Bhola, Valerie M. Jansen |
Rok vydání: |
2023 |
Popis: |
Supplementary Figure S1. RNAi screen to identify kinases that sensitize cells to CDK4/6 inhibition. Supplementary Figure S2. Calculation of the sensitivity index (SI) value. Supplementary Figure S3. PDK1 and CDK4/6 inhibitors are synergistic against a panel of cancer cell lines. Supplementary Figure S4. Inhibition of the PI3K/PDK1 pathway results in durable responses and is well-tolerated in vivo. Supplementary Figure S5. Ribociclib-resistant cells are cross-resistant to other CDK4/6 inhibitors and upregulate P-PDK1. Supplementary Figure S6. Inhibition of PI3K/PDK1/AKT/mTOR signaling pathway resensitizes ribociclib-resistant cells to CDK4/6 inhibition. |
Databáze: |
OpenAIRE |
Externí odkaz: |
|